Shanghai Junshi Biosciences Co., Ltd. (HKG:1877)
Hong Kong
· Delayed Price · Currency is HKD 19.89
+0.93 (4.91%)
Mar 10, 2026, 1:35 PM HKT
Shanghai Junshi Biosciences Employees
Shanghai Junshi Biosciences had 2,670 employees as of June 30, 2025. The number of employees increased by 92 or 3.57% since the number was reported on December 31, 2024.
Employees
2,670
Change
92
Growth
3.57%
Revenue / Employee
1.08M HKD
Profits / Employee
-377.44K HKD
Market Cap
31.56B
Employees Chart
Employees History
Related Stocks
| Company Name | Employees |
|---|---|
| Biocytogen Pharmaceuticals (Beijing) | 1,306 |
| Duality Biotherapeutics | 191 |
| Shanghai Henlius Biotech | 3,537 |
| Genscript Biotech | 5,769 |
| InnoCare Pharma | 1,176 |
| PegBio | 58 |
| 3SBio | 6,268 |
| RemeGen | 3,070 |
Shanghai Junshi Biosciences News
- 3 months ago - Junshi Biosciences Announces Acceptance of the NDA for Roconkibart (IL-17A) for the Treatment of Moderate to Severe Plaque Psoriasis - GlobeNewsWire
- 3 months ago - Junshi Biosciences Announces Primary Endpoints Met in JS001sc's Phase 3 Study for the 1ST-line Treatment of NSQ-NSCLC - GlobeNewsWire
- 5 months ago - Junshi Biosciences Announces FDA's Approval of IND Application for Phase 2/3 Clinical Study of JS207 for the Neoadjuvant Treatment of NSCLC Patients - GlobeNewsWire
- 6 months ago - Junshi Biosciences Announces the Phase 3 Study of JS005 (IL-17A) for the Treatment of Moderate to Severe Plaque Psoriasis Met Primary Endpoints - GlobeNewsWire
- 6 months ago - TREOS Bio Partners with Charité Berlin and Junshi Biosciences to Launch Pivotal Phase II Clinical Trial in Refractory MSS Colorectal Cancer - GlobeNewsWire
- 6 months ago - Junshi Biosciences Announces 2025 Interim Financial Results and Provides Corporate Updates - GlobeNewsWire